Results 231 to 240 of about 376,342 (317)

PIK3CA mutation testing and alpelisib use in metastatic breast cancer: a real-world data set. [PDF]

Acta Oncol
Drakenberg Danese MB, Vannas CP, Fagman HA, Karlsson PO, Larsson KF.   +4 more
europepmc   +1 more source

Noninvasive Characterization of Tumor Heterogeneity in HNSCC: From Clinical Utility to Biological Correlates

Advanced Science, EarlyView.
This study establishes a CT‐based radiomics framework to quantify intratumoral heterogeneity (ITH) in HNSCC. Using unsupervised clustering, tumor ROIs and VOIs are analyzed to calculate 2D/3D ITH scores. The score shows strong predictive value for prognosis and immunotherapy response, and is associated with tumor metabolism and immune microenvironment,
Xinwei Chen, Rui Liu, Yuan Zhou, Yin Xiao, Chengmin Feng, Lin Chen, Yanshi Li, Mengna Wang, Zhaobo Cheng, Yuxi Luo, Long Liu, Lijing Niu, Yue Xiang, Juan Peng, Guohua Hu, Min Pan   +15 more
wiley   +1 more source

Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2- Metastatic Breast Cancer. [PDF]

Cancer Epidemiol Biomarkers Prev
Vidal GA, Katz J, Sadetsky N, Dabrowski EC, Kaufman PA, Verret W, Stwalley B, Kalinsky K.   +7 more
europepmc   +1 more source

PGK1 Suppresses CD8+ T Cell‐Mediated Antitumor Immunity Through CCL2/CCR2/Tumor‐Associated Macrophages Axis in Hepatocellular Carcinoma

Advanced Science, EarlyView.
PGK1 in tumor cells upregulates CCL2 expression through activation of the AKT/GSK‐3β/β‐catenin signaling axis, thereby promoting the recruitment and M2 polarization of TAMs and ultimately impairing the infiltration and activation of CD8+ T cells within the HCC tumor microenvironment. ABSTRACT Patients with advanced hepatocellular carcinoma (HCC) have a
Xi Liu, Jianpeng Liu, Zhihao Zhang, Xizhi Yu, Junjie Qian, Limin Ding, Qinchuan Wu, Zhe Yang, Xing‐Yu Luo, Xinjiang Ding, Rong Su, Xiaobo Yu, Yiting Qiao, Shengyong Yin, Haiyang Xie, Lin Zhou, Yuanxing Liu, Shusen Zheng   +17 more
wiley   +1 more source

A Patient-Led Survey of Antibody Drug Conjugate Usage and Dosing for People Living With Metastatic Breast Cancer. [PDF]

J Patient Exp
Beumer A, Carlson M, Arcuri AL, Maues J, Cowden J, Walker S, Shanahan K, Collins JL, Veach AJ, Rugo HS, Burkard ME, Kalinsky KM, Bardia A, Lustberg MB, Papautsky EL, Roberson ML.   +15 more
europepmc   +1 more source

Mitochondrial Carrier SLC25A13 Drives Ferroptosis Resistance and Immune Evasion via a STAT3–IFI6 Circuit in Breast Cancer

Advanced Science, EarlyView.
SLC25A13 is identified as an immunometabolic driver of triple‐negative breast cancer that sustains ferroptosis resistance and immune evasion through a STAT3–IFI6 circuit. Pharmacologic degradation of SLC25A13 restores ferroptosis sensitivity and enhances anti‐PD‐1 efficacy, highlighting a strategy to convert immune‐cold tumors into immunotherapy ...
Yingze Zhu, Yuhan Tang, Yingcui Chen, Zhuoqi Zhang, Yige Lu, Xinyue Wang, Qiyuan Shi, Wenhui Zhao, Hui Pang   +8 more
wiley   +1 more source

New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice. [PDF]

Breast
Rugo HS, Curigliano G, Cescon DW, Penault-Llorca F, Harbeck N, Im SA, Park YH, Barrios C, Modi S, Tolaney SM, Oliveira M.   +10 more
europepmc   +1 more source

Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects

Advanced Science, EarlyView.
Nucleic acid therapeutics bypass the structural limitations of conventional drugs by targeting mRNA rather than proteins. This review examines how antisense oligonucleotides, siRNAs, miRNAs, aptamers, and mRNA vaccines intervene against historically undruggable oncoproteins including Ras, MYC, and p53, highlighting mechanistic advances, delivery ...
Feng Xu, Ke Wang, Kaizhong Lu, Tianlun Hou, Yuan Chen, Xian Wang, Hongchuan Jin   +6 more
wiley   +1 more source

mTORC2 Phosphorylation of GSDME‐N Drives Cullin4B‐Mediated Proteasomal Degradation to Suppress Pyroptosis and Confer Radioresistance in Small Cell Lung Cancer

Advanced Science, EarlyView.
Radioresistance severely limits the efficacy of therapies for small cell lung cancer (SCLC). This study reveals a novel mechanism of resistance driven by the active suppression of pyroptosis. Specifically, the mTORC2 complex directly phosphorylates GSDME‐N and promotes its CUL4B‐mediated ubiquitination and proteasomal degradation.
Qing‐qing Xu, Ci‐ming Sun, Sui‐xian Zhang, Rui Li, Chen‐fei Wu, Zai‐shan Lin, Li Li, Run‐zhe Chen, Qi‐wen Li, Yuan‐yuan Chen, Xuan Li, Ming Chen   +11 more
wiley   +1 more source

Disparities in Disease Presentation and Treatment Initiation for De Novo Metastatic Breast Cancer.

JAMA Netw Open
Freeman JQ, Ravichandran A, Poland S, Hennessy MA, Guo W, Nanda R.   +5 more
europepmc   +1 more source